Black Diamond Therapeutics, Inc. [NASDAQ: BDTX] disclosed that it has joined forces with OpenEye Scientific. As per the strategic partnership, OpenEye’s Orion molecular design platform will be integrated with Black Diamond’s proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine to promote Black Diamond’s efforts to develop MasterKey inhibitor cancer therapies.
Orion Software-as-a-Service platform of OpenEye will allow Black Diamond to perform quick simulations and assessment of protein motion through Orion’s powerful combination of a high-performance computing facility, scientific development environment, and browser-based analysis and collaboration tools.
Furthermore, the Orion molecular design platform of OpenEye will be consolidated with the Amazon Web Services Cloud environment. It will enable Black Diamond to engage in scalable and parallel analyses of the conformational states of families of mutant oncogenes. Black Diamond and OpenEye will join hands to co-develop improved sampling capabilities created to provide information on an enhanced time scale.
Additionally, Black Diamond will improve its ability to discover mutant selective MasterKey therapies that target families of oncogenic mutations. The strategic partnership agreement between OpenEye and Black Diamond includes an upfront payment and potential downstream economics that results from the select Black Diamond products for OpenEye.